• Markets
• News

• Immunoprecise Antibodies Ltd IPA.OQ reported a quarterly adjusted loss of 11 cents​​ per share for the quarter ended in April, higher than the same quarter last year, when the company reported EPS of -21 cents. The mean expectation of two analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -13 cents to -10 cents per share.

• Revenue rose 15.3% to C$6.46 million from a year ago; analysts expected $6.53 million.

• Immunoprecise Antibodies Ltd's reported EPS for the quarter was a loss of 70 cents​.

• The company reported a quarterly loss of C$18.05 million.

• Immunoprecise Antibodies Ltd shares had fallen by 14.9% this quarter and lost 49.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," "hold" and "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd is $7.00

This summary was machine generated from LSEG data July 29 at 03:52 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)